Cogent is focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Lead program, bezuclastinib, is being developed for Systemic Mastocytosis and Gastrointestinal Stromal Tumors. In addition, the Research Team is developing a portfolio of novel therapies initially targeting ErbB2 and FGFR2.